NCT02816762View on ClinicalTrials.gov

CPAP Effect on Albuminuria in Patients With Diabetic Nephropathy and Obstructive Sleep Apnea

PHASE4CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Diabetic NephropathySleep Apnea
Interventions
DEVICE

Continuous positive airway pressure

Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).

DRUG

Pharmacological treatment

Conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.

OTHER

Diet

Conventional anti-diabetic diet recommendations

Trial Locations (6)

19002

Hospital Universitario General de Guadalajara, Guadalajara

28034

Hosptial Universitario La Paz, IdiPAZ, Madrid

28040

Fundación Jiménez Díaz, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28703

Hospital Universitario Infanta Sofía, San Sebastián de los Reyes

07120

Hospital Universitari Son Espases, Palma de Mallorca

All Listed Sponsors
lead

Hospital Universitario La Paz

OTHER

NCT02816762 - CPAP Effect on Albuminuria in Patients With Diabetic Nephropathy and Obstructive Sleep Apnea | Biotech Hunter | Biotech Hunter